Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 12, 2009, Pages 3689-3702

  Bezençon, Olivier ^a   Bur, Daniel ^a   Weller, Thomas ^a   Richard Bildstein, Sylvia ^a   Remeň, Luboš ^a   Sifferlen, Thierry ^a   Corminboeuf, Olivier ^a   Grisostomi, Corinna ^a   Boss, Christoph ^a   Prade, Lars ^a   Delahaye, Stéphane ^a   Treiber, Alexander ^a   Strickner, Panja ^a   Binkert, Christoph ^a   Hess, Patrick ^a   Steiner, Beat ^a   Fischli, Walter ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,9 DIAZABICYCLO[3.3.1]NONENE DERIVATIVE; BICYCLO COMPOUND; HETEROCYCLIC COMPOUND; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG CONFORMATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; IC 50; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AZABICYCLO COMPOUNDS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RENIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67549146537     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900022f     Document Type: Article

References (50)

1. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
2. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertens. 2003, 21, 1983-1992.
3. For recent reviews, see the following: (a) Carey, R. M.; Stragy, H. M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 2003, 24, 261-271.
4. (b) Persson, P. B. Renin: origin, secretion and synthesis. J. Physiol. 2003, 552, 667-671. (Pubitemid 37428411)
5. (c) Re, R. N. Tissue renin angiotensin system. Med. Clin. North Am. 2004, 88, 19-38.
6. (d) Brewster, U. C.; Perazella, M. A. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 2004, 116, 263-272. (Pubitemid 38224234)
7. (e) Aneja, A.; El-Atat, F.; McFarlane, S. I.; Sowers, J. R. Hypertension and obesity. Recent Prog. Horm. Res. 2004, 59, 169-205.
8. (f) Cooper, M. E. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am. J. Hypertens 2004, 17, 265-1205
9. (g) Remuzzi, G.; Perico, N.; Macia, M.; Ruggenenti, P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005, 68, S57-S63. (Pubitemid 44324688)
10. (h) Casas, J. P.; Chua, W.; Loukogeorgakis, S.; Vallance, P.; Smeeth, L.; Hingorani, A. D.; MacAllister, R. J. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366, 2026-2032.
11. (i) Brown, N. J.; Vaughan, D. E.; Fogo, A. B. The renin-angiotensin- aldosterone system and fibrinolysis in progressive renal disease. Semin. Nephrol. 2002, 22, 399-406. (Pubitemid 35024516)
12. (j) Tylicki, L.; Larczynski, W.; Rutkowski, B. Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney Blood Pressure Res. 2005, 28, 230-242. (Pubitemid 43048613)
13. (k) Sun, Y. The renin-angiotensin-aldosterone system and vascular remodeling. Congestive Heart Failure 2002, 8, 11-16. (Pubitemid 34456113)
14. Rosenberg, S. H.; Spina, K. P.; Condon, S. L.; Polakowski, J.; Yao, Z.; Kovar, P.; Stein, H. H.; Cohen, J.; Barlow, J. L.; Klinghofer, V.; Egan, D. A.; Tricarico, K. A.; Perun, T. J.; Baker, W. R.; Klienert, H. D. Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3-[[(1-methylpiperazin- 4-yl)sulfonyl]propionyl]3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1- cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517). J. Med. Chem. 1993, 36, 460-467. (Pubitemid 23065305)
15. (a) Nussberger, J.; Wuerzner, G.; Jensen, C.; Brunner, H. R. Angiotensin II suppression in human by the orally active renin inhibitor aliskiren (SPP100). Hypertension 2002, 1-8.
16. (b) Stanton, A. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. J. Renin-Angiotensin-Aldosterone Syst. 2003, 4, 6-10.
17. (c) Stanton, A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. CardioVasc. Drugs 2003, 3, 389-394. (Pubitemid 38008675)
18. (d) Gradman, A. H.; Schmieder, R. E.; Lins, R. L.; Nussberger, J.; Chiang, Y.; Bedigian, M. P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 1012-1018. (Pubitemid 40354519)
19. (e) Azizi, M.; Webb, R.; Nussberger, J.; Hollenberg, N. K. Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. 2006, 24, 243-256. (Pubitemid 43348229)
20. (f) Göschke, R.; Stutz, S.; Rasetti, V.; Cohen, N.-C.; Rahuel, J.; Rigollier, P.; Baum, H.-P.; Forgiarini, P.; Schnell, C. R.; Wagner, T.; Gruetter, M. G.; Fuhrer, W.; Schilling, W.; Cumin, F.; Wood, M. J.; Maibaum, J. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. J. Med. Chem. 2007, 4818-4831. (Pubitemid 47525467)
21. (g) Maibaum, J.; Stutz, S.; Göschke, S.; Rigollier, P.; Yamaguchi, Y.; Cumin, F.; Rahuel, J.; Baum, H.-P.; Cohen, N.-C.; Schnell, C. R.; Fuhrer, W.; Gruetter, M. G.; Schilling, W.; Wood, J. M. Structural modification of the P2′ position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl- octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. J. Med. Chem. 2007, 4832-4844. (Pubitemid 47525468)
22. (a) Vieira, E.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Güller, R.; Hirth, G.; Märki, H. P.; Müller, M.; Oefner, C.; Scalone, M.; Stadler, H.; Wilhelm, M.; Wostl, W. Substituted piperidines. Highly potent renin inhibitors due to induced fit adaptation of the active site. Bioorg. Med. Chem. Lett. 1999, 9, 1397-1402. (Pubitemid 29232215)
23. (b) Güller, R.; Binggeli, A.; Breu, V.; Bur, D.; Fischli, W.; Hirth, G.; Jenny, C.; Kansy, M.; Montavon, F.; Müller, M.; Oefner, C.; Stadler, H.; Vieira, E.; Wilhelm, M.; Wostl, W.; Märki, H. P. Piperidine-renin inhibitors compounds with improved physicochemical properties. Bioorg. Med. Chem. Lett. 1999, 9, 1403-1408. (Pubitemid 29232216)
24. (c) Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J.-P.; D'Arcy, A.; Dorn, A.; Fischli, W.; Grüinger, F.; Güller, R.; Hirth, G.; Märki, H. P.; Mathews, S.; Müller, M.; Ridley, R. G.; Stadler, H.; Vieira, E.; Wilhelm, M.; Winkler, F. K.; Wostl, W. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases. Chem. Biol. 1999, 6, 127-131. (Pubitemid 29363148)
25. (d) Marki, H. P.; Binggeli, A.; Bittner, B.; Bohner-Lang, V.; Breu, V.; Bur, D.; Coassolo, Ph.; Clozel, J. P.; D'Arcy, A.; Doebeli, H.; Fischli, W.; Funk, Ch.; Foricher, J.; Giller, T.; Gruninger, F.; Guenzi, A.; Guller, R.; Hartung, T.; Hirth, G.; Jenny, Ch.; Kansy, M.; Klinkhammer, U.; Lave, T.; Lohri, B.; Luft, F. C.; Mervaala, E. M.; Muller, D. N.; Muller, M.; Montavon, F.; Oefner, Ch.; Qiu, C.; Reichel, A.; Sanwald-Ducray, P.; Scalone, M.; Schleimer, M.; Schmid, R.; Stadler, H.; Treiber, A.; Valdenaire, O.; Vieira, E.; Waldmeier, P.; Wiegand-Chou, R.; Wilhelm, M.; Wostl, W.; Zell, M.; Zell, R. Piperidine renin inhibitors: from leads to drug candidates. Farmaco 2001, 56, 21-27. (Pubitemid 32372577)
26. (e) Bursavich, M. G.; West, C. W.; Rich, D. H. From peptides to non-peptide peptidomimetics: design and synthesis of new piperidine inhibitors of aspartic peptidases. Org. Lett. 2001, 3, 2317-2320. (Pubitemid 33629494)
27. (a) Powell, N. A.; Clay, E. H.; Holsworth, D. D.; Bryant, J. W.; Ryan, M. J.; Jalaie, M.; Edmunds, J. J. Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 4713-4716. (Pubitemid 41354794)
28. (b) Powell, N. A.; Clay, E. H.; Holsworth, D. D.; Bryant, J. W.; Ryan, M. J.; Jalaie, M.; Zhang, E.; Edmunds, J. J. Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2371-2374. (Pubitemid 40523102)
29. (c) Holsworth, D. D.; Cai, C.; Cheng, X.-M.; Cody, W. L.; Downing, D. M.; Erasga, N.; Lee, C.; Powell, N. A.; Edmunds, J. J.; Stier, M.; Jalaie, M.; Zhang, E.; McConnell, P.; Ryan, M. J.; Bryant, J.; Li, T.; Kasani, A.; Hall, E.; Subedi, R.; Rahim, M.; Maiti, S. Ketopiperazine-based renin inhibitors: optimization of the "C" ring. Bioorg. Med. Chem. Lett. 2006, 16, 2500-2504.
30. Holsworth, D. D.; Jalaie, M.; Belliotti, T.; Cai, C.; Collard, W.; Ferreira, S.; Powell, N. A.; Stier, M.; Zhang, E.; McConnell, P.; Mochalkin, I.; Ryan, M. J.; Bryant, J.; Li, T.; Kasani, A.; Subedi, R.; Maiti, S. N.; Edmunds, J. J. Discovery of 6-ethyl-2,4-diaminopyrimidines-based small molecule renin inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 3575-3580. (Pubitemid 46898825)
31. (a) Bermudez, J.; Gaster, L.; Gregory, J.; Jerman, J.; Joiner, G. F.; King, F. D.; Rahman, S. K. Synthesis and 5-HT3 receptor antagonist potency of novel endo-3,9-diazabicyclo[3.3.1]nonan-7-amine derivatives. Bioorg. Med. Chem. Lett. 1994, 4, 2373-2376. (Pubitemid 24324543)
32. (b) Gregory, J. A.; Jennings, A. J.; Joiner, G. F.; King, F. D.; Rahman, S. K. Synthesis of (endo) 3,9-disubstituted diazabicyclo[3.3.1]nonan-7-amines. Tetrahedron Lett. 1995, 36, 155-158.
33. An enantioselective acylation using conditions described in the following reference worked as well, yielding the desired β-ketoester in a 9:1 ratio of enantiomers: Majewski, M.; Lazny, R. Synthesis of tropane alkaloids via enantioselective deprotonation of tropinone. J. Org. Chem. 1995, 60, 5825-5830.
34. (a) Olofson, R. A.; Yamamoto, Y. S.; Wancowicz, D. J. Use of the vinylcarbonyl group for amino protection in peptide synthesis. Tetrahedron Lett. 1977, 1563-1566. (Pubitemid 8181951)
35. (b) Olofson, R. A.; Schnur, R. C.; Bunes, L.; Pep, J. P. Selective N-dealkylation of tertiary amines with vinyl chloroformate: an improved synthesis of naxolone. Tetrahedron Lett. 1977, 1567-1570. (Pubitemid 8081232)
36. (c) Olofson, R. A.; Martz, J. T.; Senet, J. P.; Piteau, M.; Malfroot, T. A new reagent for the selective high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine. J. Org. Chem. 1984, 49, 2081-2082. (Pubitemid 14094688)
37. A transprotection with 2,2,2-trichloroethyl chloroformate proceeds as well, but the resulting 2,2,2-chloroethyl carbamate was not stable enough in the next steps.
38. Amide couplings under strictly identical conditions were conducted in parallel with the two separated regioisomers of carboxylic acids 21a and 21b. The amide products were identically the compounds 22a and 22b, in the same regioisomeric ratio, whatever the starting regioisomer was taken. This indicates an equilibration of the double bond position on an activated intermediate during the amide coupling.
39. The racemic compounds (rac)-26a to (rac)-26d were prepared as described for the enantiomerically pure compounds but starting from (rac)-6, without any resolution with tartaric acid (see Supporting Information for details).
40. Lévesque; J.-F.; et al. Manuscript in preparation; Merck Frosst.
41. (a) Brockway, B. P.; Mills, P. A.; Azar, S. H. A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radio-telemetry. Clin. Exp. Hypertens., Part A 1991, 13, 885-895.
42. (b) Guiol, C.; Ledoussal, C.; Surgé, J.-M. A radiotelemetry system for chronic measurement of blood pressure and heart rate in the unrestrained rat validation of the method. J. Pharmcol. Toxicol. Methods 1992, 28, 99-105.
43. (c) Hess, P.; Clozel, M.; Clozel, J.-P. Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J. Appl. Physiol. 1996, 81, 1027-1032. (Pubitemid 26303261)
44. (a) Bohlender, J.; Fukamizu, A.; Lippoldt, A.; Nomura, T.; Dietz, R.; Menard, J.; Murakami, K.; Luft, F. C.; Ganten, D. High human renin hypertension in transgenic rats. Hypertension 1997, 29, 428-434. (Pubitemid 27074079)
45. (b) Mervaala, E. M. A.; Dehmel, B.; Gross, V.; Lippoldt, A.; Bohlender, J.; Milia, A. F.; Ganten, D.; Luft, F. C. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J. Am. Soc. Nephrol. 1999, 10, 1669-1680. (Pubitemid 29364665)
46. (c) Luft, F. C.; Mervaala, E. M. A.; Muller, D. N.; Gross, V.; Schmidt, F.; Park, J. K.; Schmitz, C.; Lippoldt, A.; Breu, V.; Dechend, R.; Dragun, D.; Schneider, W.; Ganten, D.; Haller, H. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999, 33, 212-218.
47. (d) Muller, D. N.; Dechend, R.; Mervaala, E. M. A.; Park, J.-K.; Schmidt, F.; Fiebeler, A.; Theuer, J.; Breu, V.; Ganten, D.; Haller, H.; Luft, F. C. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000, 35, 193-201. (Pubitemid 30054172)
48. Holsworth, D. D.; Powell, N. A.; Downing, D. M.; Cai, C.; Cody, W. L.; Ryan, J. M.; Ostroski, R.; Jalaie, M.; Bryant, J. W.; Edmunds, J. J. Discovery of novel non-peptidic ketopiperazine-based renin inhibitors. Bioorg. Med. Chem. 2005, 13, 2657-2664. (Pubitemid 40341668)
49. Piazzi, L.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; Andrisano, V.; Recanatini, M.; Rampa, A. Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[ω-(benzylmethylamino) alkoxy]xanthen-9-ones. Bioorg. Med. Chem. 2007, 15, 575-585. (Pubitemid 44738548)
50. Morita, C.; Hashimoto, K.; Okuno, T.; Shirahama, H. Synthesis of 3-trifluoromethyl-3-aryldiazirines for photoaffinity-labeling probes and their labeling ability. Heterocycles 2000, 52, 1163-1169.